Table 4

Risk of major adverse liver outcomes at 10 years according to intention-to-treat analyses in subgroups

No of events, GLP1 agonist initiatorsNo of events, non-initiatorsAbsolute risk (%), GLP1 agonist initiators
(95% CI)
Absolute risk (%), non-initiators
(95% CI)
Risk difference (%) (95% CI)Risk ratio (95% CI)
Liver disease aetiology
 MASLD2130315.8 (5.0 to 26.5)11.2 (9.1 to 13.2)4.6 (-5.5 to 14.8)1.41 (0.53 to 2.30)
 Other than MASLD2168813.1 (2.6 to 23.6)17.3 (14.5 to 20.2)−4.2 (-14.9 to 6.4)0.76 (0.15 to 1.36)
Cirrhosis status at baseline
 Compensated cirrhosis2328636.5 (6.6 to 66.3)34.6 (26.8 to 42.5)1.9 (-27.6 to 31.4)1.05 (0.20 to 1.91)
 No cirrhosis195468.9 (2.9 to 14.9)10.9 (9.1 to 12.6)−1.9 (-7.8 to 3.9)0.82 (0.29 to 1.36)
  • .GLP1, glucagon-like peptide-1 receptor; MASLD, metabolic dysfunction-associated steatotic.